Oncolytics Biotech KOL Webinar on Pancreatic Cancer and Interim Results from the Phase 1/2 GOBLET Study Being Presented at the SITC 37th Annual Meeting
|DATE:||November 14, 2022|
|TIME:||10:00 AM EST|
About The Event
Join us for a virtual key opinion leader (KOL) event with Oncolytics Biotech, featuring Dirk Arnold, MD, PhD (Asklepios Tumorzentrum Hamburg), Andrea Bullock, MD, MPH (Beth Israel Deaconess Medical Center) and Thomas Seufferlein, MD, PhD (Ulm University, Germany).
During the event, the KOLs and members of the Oncolytics management team will discuss the current treatment landscape and unmet medical need in pancreatic cancer, as well as interim results from the Phase 1/2 GOBLET study’s pancreatic cancer cohort being presented at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.
A live question and answer session will follow the formal presentations.